F8 and hemophilia A: <h4>Introduction</h4>The therapeutic landscape for patients with haemophilia A (PwHA) is rapidly evolving with the introduction of extended half-life FVIII (EHL-FVIII) and non-FVIII therapies that mimic FVIII, such as emicizumab (EMI).